{"name":"Agenus","slug":"agenus","ticker":"AGEN","exchange":"NASDAQ","domain":"agenusbio.com","description":"Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.","hq":"Lexington, MA","founded":0,"employees":"81","ceo":"Garo H. Armen","sector":"Immuno-Oncology / Bispecifics","stockPrice":3.56,"stockChange":0.09,"stockChangePercent":2.59,"marketCap":"$148M","metrics":{"revenue":123866000,"revenueGrowth":40.2,"grossMargin":96.9,"rdSpend":79338000,"netIncome":-37730000,"cash":34996000,"dividendYield":0,"peRatio":1.7,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"balstilimab patent cliff ($0.0B at risk)","drug":"balstilimab","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"balvetinib patent cliff ($0.0B at risk)","drug":"balvetinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"AGEN1571","genericName":"AGEN1571","slug":"agen1571","indication":"Other","status":"phase_1"},{"name":"AG-707","genericName":"AG-707","slug":"ag-707","indication":"Other","status":"phase_1"},{"name":"AGEN1777","genericName":"AGEN1777","slug":"agen1777","indication":"Other","status":"phase_1"},{"name":"AGEN1884","genericName":"AGEN1884","slug":"agen1884","indication":"Other","status":"phase_2"},{"name":"Balstililmab","genericName":"Balstililmab","slug":"balstililmab","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HSPPC-96 or Oncophage","genericName":"HSPPC-96 or Oncophage","slug":"hsppc-96-or-oncophage","indication":"Metastatic melanoma (adjuvant setting)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"HerpV and QS-21","genericName":"HerpV and QS-21","slug":"herpv-and-qs-21","indication":"Herpes simplex virus 2 (HSV-2) infection","status":"phase_2"}]}],"pipeline":[{"name":"AGEN1571","genericName":"AGEN1571","slug":"agen1571","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AG-707","genericName":"AG-707","slug":"ag-707","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGEN1777","genericName":"AGEN1777","slug":"agen1777","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGEN1884","genericName":"AGEN1884","slug":"agen1884","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Balstililmab","genericName":"Balstililmab","slug":"balstililmab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HSPPC-96 or Oncophage","genericName":"HSPPC-96 or Oncophage","slug":"hsppc-96-or-oncophage","phase":"phase_3","mechanism":"HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells.","indications":["Metastatic melanoma (adjuvant setting)","Renal cell carcinoma (adjuvant setting)"],"catalyst":""},{"name":"HerpV and QS-21","genericName":"HerpV and QS-21","slug":"herpv-and-qs-21","phase":"phase_2","mechanism":"Stimulates the immune system by activating CD4+ T cells through the QS-21 adjuvant","indications":["Herpes simplex virus 2 (HSV-2) infection"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Agenus Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Agenus reported fourth quarter and full year 2023 financial results, with a net loss of $43.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-04","type":"deal","headline":"Agenus Announces Collaboration with Merck to Develop Cancer Therapies","summary":"Agenus announced a collaboration with Merck to develop cancer therapies using Agenus' proprietary technology.","drugName":"","sentiment":"positive"},{"date":"2023-09-25","type":"trial","headline":"Agenus Announces Positive Topline Results from Phase 2 Trial of Balstilimab in Cervical Cancer","summary":"Agenus announced positive topline results from a Phase 2 trial of balstilimab in cervical cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-17","type":"earnings","source":"simplywall.st","summary":"Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative - simplywall.st","headline":"Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOSUdsekZ0Qko4RlVTcmZxWHlLeFd2N3pQSnJ3T09qVTZOVnpVX0R3YVo3NUxSNjRMNl8zdk5kQ0EyczFLbVhrZnk5RFVzSkRsVks4SXFfQ3drdmVzVnV6NERHejQ4YnBJNG02VlJPaGhsVlRVOXlJTlFBaC14QmlTUm5qS0VUVHBrQ1d2bjk3SlBqMDYzZ3ZSX0ZxNnlQVXk1NEhYVFZrR3JvTENyeWNjQ19PZElPR0RlMFFNRlpEeUp5UVVOV0ZPT1JKdDBCVE50TzRpYWQwQlRNRVlWeWo1d1plZzRHdVBvVGF4R2Z1TmRQRjRUTldmYXhmQzJoS1d6Qy1lUTFpaElpZVZoVEdXWlY2SzJvOG1iZm5BN19R?oc=5","date":"2026-01-15","type":"pipeline","source":"PR Newswire","summary":"Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - PR Newswire","headline":"Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY0ktVTEzX1RWNVhPWGthWExTdk5kQ1otem0yN3EtS1p0MFNBanVaTktrVEwtUnJMemFYRV9QbFZFSXNXZWFPN0JJazVOWGRYdmxiQ3Z6aXIzenRNQVM5R2tycldtU2pRRjF6VW9qVU9xcVVxU3ZCb00wNmI0ZE5XVHJXMmVVd0I4TWZUeVBxWlZvNjFQZHpscU5PbGtJRGJPS3prWk5ZcmQ5Zzk2alYwVndsXzZqOEtQT3h6bEQ4Ri0?oc=5","date":"2026-01-15","type":"pipeline","source":"Stock Titan","summary":"New Zylidac Bio sites help secure U.S. biologic drug supply chains - Stock Titan","headline":"New Zylidac Bio sites help secure U.S. biologic drug supply chains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPTmJYZEtab051R01aOVNkRG45bEVwd2xHTTE0VWltcGlNQ1M4OHhaZ2ZqcEFEVDFKNGJKZEtKc3EyWEZyNWNxR2VZdnFvaXJfYXV6R0hJbGRpT3VEWHBZN0xhd2hQR2JHWGg5RzdxRUtpWUxwMWZqcERRUjdlT1dlOGhYc1p4YnpXblpLbUcwNEtNTlp3VXdhU29Vb2p1RHg4NFFyZUVBMEI2Yy1TU2ZtWTdiaFYtR282LVpCOWlXck9fRE80MXQ3dlBnNEVWOHdOeFpGeDZVVGhtcUlTTFVKbDJXSUhiWlJqbUxqSjhmcVpxWVJTczVNMkZWWkhGVnpKY2NYUnlpODFlV2VNZW54UVBuWDFVSWQ3T01zRk56WXBRTXRJOHpGSHBB?oc=5","date":"2026-01-15","type":"deal","source":"Business Wire","summary":"Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - Business Wire","headline":"Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S.","sentiment":"neutral"},{"date":"2026-01-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPNzlDMWNEVjBCMW1jeWE2ak42UEczTFhUMmpHNnYxWmpwOEZNcTUyUEJ4dVQ3UUZmQmRuS3R5VF9NYVM3T1BkVTVWM0xsdUF5SjBzOXI3Z3hIelpsdTB3UXJlVGNrQkdyNHdPd3FjQnNQRnBhWHpiTUhFVWhtQ3ItSWZn?oc=5","date":"2025-11-10","type":"earnings","source":"Yahoo Finance","summary":"Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates - Yahoo Finance","headline":"Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPemZXOTlDR0lqR0d2MUFsdzlXR3g2VUgtYXd0WEZRa2NBSW9XaVcycEgwYzlDNVA3TkE5MkhHcF8xZG1LQ19GUlJGRWdSYkVlNWxXQlpnWVc2c1dFSl8tTnB5NFUzOG9IRzFfWEJwZF9HV2JMRFJpRG9nci1JVVdUbkxncnFjYm1odHp0M2JNWFotcmtoeEN3UDBFVWxUa0FyRm9WV2VhNjZkQWVJ?oc=5","date":"2025-11-10","type":"earnings","source":"GuruFocus","summary":"Agenus (AGEN) Reports Strong Q3 Earnings with Revenue Surge - GuruFocus","headline":"Agenus (AGEN) Reports Strong Q3 Earnings with Revenue Surge","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOelNGRE9weHEwZDhKWkhZNHFHWUpRUklvVUQ2RHRiWU82cW9GcUtfRHJkSHprTWRJWnREaGlJemR4R1NIck5GSEFXbDFUZUZ2T3JMNlM5R3cycGVaM1Q1SjFyXzZnLUVnU0hscW4wZVhIVVhGcFppMkNpVkc1cGlMaGZUR2c3NTIxRFhBbllremJWdjZaWEYxYWRfa0JKclJHb3JQZFdlYXkxLURLUkZpTWNtMk1mY0Q3RERHOTN0U3B5cUVtWHBV?oc=5","date":"2025-09-23","type":"earnings","source":"Investing.com","summary":"Agenus and Zydus transactions face new CFIUS review, closing shifts to Q4 - Investing.com","headline":"Agenus and Zydus transactions face new CFIUS review, closing shifts to Q4","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNUkhMSkl2SkZ4M3FBWklHSFIyRFdSRmEyc1RBVDhYSTNMQmctYTQ0TjIwT0NJMnVLejBoU24zaURIV2IwTG5Mc0xOVC1lOUM5LTFXTU1wTG52eHBtMDFTZDFyZ3AtLUd5a1BGNU0xcnRxR0RSOUYxaVhyRmRYaEdBUTJoYW8yUHNOTUM2RER0ZEpQaHJSMUJQa05iTEd6VjNsT2c?oc=5","date":"2025-08-12","type":"pipeline","source":"Seeking Alpha","summary":"Agenus: Cash Starved Pharma Counting On Bot/Bal Cancer Bounty (NASDAQ:AGEN) - Seeking Alpha","headline":"Agenus: Cash Starved Pharma Counting On Bot/Bal Cancer Bounty (NASDAQ:AGEN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9vYktKY1NtQWpUMnlxdjFPeHdKeHpxMnB2OUZiTGs1Vk1BbEZ3enB0SkhoYVpZMWVBelhCUzQzWS0xdFNabzRYeF9lZnFSbFNUZTZLY05ya1lQSGsySjgwUU14UjFTNG43WjhOblZDMHFtWEF5SnNyR3BoT0gxZw?oc=5","date":"2025-08-11","type":"earnings","source":"Yahoo Finance","summary":"Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance","headline":"Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates","sentiment":"positive"}],"patents":[{"drugName":"balstilimab","drugSlug":"balstilimab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"balvetinib","drugSlug":"balvetinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":7,"phaseCounts":{"phase_1":3,"phase_2":3,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-Oncology","Bispecifics"],"financials":{"source":"sec_edgar+yahoo","revenue":42877086,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":42877086,"period":"2017-12-31"},{"value":8354000,"period":"2017-12-31"},{"value":3359000,"period":"2017-09-30"},{"value":4208000,"period":"2017-06-30"},{"value":26956000,"period":"2017-03-31"}],"grossProfit":33836000,"grossProfitHistory":[{"period":"2025-12-31","value":33836000},{"period":"2024-12-31","value":-52551000},{"period":"2023-12-31","value":-81366000},{"period":"2022-12-31","value":-99235000}],"rdSpend":79338000,"rdSpendHistory":[],"sgaSpend":54392000,"operatingIncome":-20556000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-20556000},{"period":"2024-12-31","value":-124429000},{"period":"2023-12-31","value":-160105000},{"period":"2022-12-31","value":-180242000}],"netIncome":-37730000,"netIncomeHistory":[{"period":"2025-12-31","value":115000},{"period":"2024-12-31","value":-227212000},{"period":"2023-12-31","value":-245761000},{"period":"2022-12-31","value":-220074000}],"eps":-10.59,"epsHistory":[{"period":"2024-12-31","value":-10.59},{"period":"2023-12-31","value":-13.75},{"period":"2022-12-31","value":-15.64},{"period":"2021-12-31","value":-2.2}],"cash":2998000,"cashHistory":[{"period":"2025-12-31","value":2998000},{"period":"2024-12-31","value":40437000},{"period":"2023-12-31","value":76110000},{"period":"2022-12-31","value":178674000}],"totalAssets":226798000,"totalLiabilities":504659000,"totalDebt":55899000,"equity":-271111000,"operatingCashflow":-77195000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-77195000},{"period":"2024-12-31","value":-158315000},{"period":"2023-12-31","value":-224202000},{"period":"2022-12-31","value":-175373000}],"capex":-6000,"capexHistory":[{"period":"2025-12-31","value":-6000},{"period":"2024-12-31","value":-576000},{"period":"2023-12-31","value":-9954000},{"period":"2022-12-31","value":-53062000}],"freeCashflow":-77201000,"dividendsPaid":null,"buybacks":-87000,"employees":81,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":12295000,"ebit":5407000,"ebitda":6004000,"period":"2025-12-31","revenue":34204000,"epsBasic":null,"netIncome":-10578000,"rdExpense":null,"epsDiluted":null,"grossProfit":26693000,"operatingIncome":14398000},{"sga":10860000,"ebit":77081000,"ebitda":80112000,"period":"2025-09-30","revenue":30235000,"epsBasic":2,"netIncome":63914000,"rdExpense":null,"epsDiluted":1.94,"grossProfit":5997000,"operatingIncome":-4863000},{"sga":15518000,"ebit":-16723000,"ebitda":-13555000,"period":"2025-06-30","revenue":25691000,"epsBasic":-1,"netIncome":-27955000,"rdExpense":null,"epsDiluted":-1,"grossProfit":-1262000,"operatingIncome":-16780000},{"sga":15718000,"ebit":-13575000,"ebitda":-10372000,"period":"2025-03-31","revenue":24066000,"epsBasic":-1.03,"netIncome":-25266000,"rdExpense":null,"epsDiluted":-1.03,"grossProfit":2407000,"operatingIncome":-13311000},{"sga":20931000,"ebit":-26120000,"ebitda":-22860000,"period":"2024-12-31","revenue":26837000,"epsBasic":null,"netIncome":-45859000,"rdExpense":null,"epsDiluted":null,"grossProfit":-7056000,"operatingIncome":-27987000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-3.08,"netIncome":null,"rdExpense":null,"epsDiluted":-3.08,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.56,"previousClose":3.47,"fiftyTwoWeekHigh":7.34,"fiftyTwoWeekLow":2.71,"fiftyTwoWeekRange":"2.71 - 7.34","fiftyDayAverage":3.75,"twoHundredDayAverage":3.92,"beta":0,"enterpriseValue":143815232,"forwardPE":-1.6,"priceToBook":-0.62,"priceToSales":1.2,"enterpriseToRevenue":1.16,"enterpriseToEbitda":9.47,"pegRatio":0,"ebitda":15188000,"ebitdaMargin":12.3,"freeCashflow":-50640876,"operatingCashflow":-87527000,"totalDebt":41074000,"debtToEquity":0,"currentRatio":0.38,"returnOnAssets":2.5,"returnOnEquity":0,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":2,"targetMeanPrice":15.5,"targetHighPrice":23,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.7,"institutionHeldPercent":24.8,"sharesOutstanding":41642431,"floatShares":38628768,"sharesShort":4387571,"shortRatio":3.97,"shortPercentOfFloat":10.6,"epsTrailing":2.05,"epsForward":-2.3,"revenuePerShare":3.74,"bookValue":-5.74,"officers":[{"age":72,"name":"Dr. Garo H. Armen Ph.D.","title":"Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman"},{"age":64,"name":"Dr. Steven J. O'Day M.D., Ph.D.","title":"Chief Medical Officer"},{"age":50,"name":"Dr. Jennifer S. Buell Ph.D.","title":"Director and President & CEO of MiNK Therapeutics"},{"age":36,"name":"Mr. Austin  Charette","title":"Senior Director, Financial Reporting and Compliance & Principal Accounting Officer"},{"age":null,"name":"Craig  Winter","title":"Chief Information Officer"},{"age":null,"name":"Mr. Zack  Armen","title":"Vice President of Investor Relations & Corporate Development"},{"age":null,"name":"Ms. Stefanie  Perna-Nacar","title":"Chief Communications & Government Relations Officer"},{"age":null,"name":"Ms. Tracy Mazza Clemente","title":"Chief People Officer"}],"industry":"Biotechnology","irWebsite":"http://www.agenusbio.com/investors/performance.shtml","website":"https://www.agenusbio.com","phone":"781 674 4400"}}